Ola Weiland

Publications
CV
Public outreach and news

Articles

Article: INFECTIOUS DISEASES. 2023;55(11):786-793
Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct acting anti-virals, but salvage therapy may be life-saving
Westin J; Ydreborg M; Kampmann C; Wejstal R; Weiland O
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(6):1059-1070
Value appropriation in hepatitis C
Lindgren P; Lofvendahl S; Bradvik G; Weiland O; Jonsson B
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2021;56(7):855-861
Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection
Waldenstrom J; Kaberg M; Alanko Blome M; Widell A; Bjorkman P; Nilsson S; Hammarberg A; Weiland O; Nystrom K; Lagging M
Article: JOURNAL OF VIRAL HEPATITIS. 2021;28(1):142-146
Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals
Lindgren P; Lofvendahl S; Bradvik G; Weiland O
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2020;64(12):e01417-e01420
Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity
Mejer N; Fahnoe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
Article: HEPATOLOGY. 2020;72(4):1177-1190
Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes
Kamal H; Westman G; Falconer K; Duberg A-S; Weiland O; Haverinen S; Wejstal R; Carlsson T; Kampmann C; Larsson SB; Bjorkman P; Nystedt A; Cardell K; Svensson S; Stenmark S; Wedemeyer H; Aleman S
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2020;55(5):574-580
High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder
Kaberg M; Larsson SB; Jerkeman A; Nystedt A; Duberg A-S; Kovamees J; Ydreborg M; Aleman S; Busch K; Blome MA; Weiland O; Soderholm J
Article: INFECTIOUS DISEASES. 2020;52(5):336-346
Significant decrease in injection risk behaviours among participants in a needle exchange programme
Kaberg M; Karlsson N; Discacciati A; Widgren K; Weiland O; Ekstrom AM; Hammarberg A
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2019;54(3):319-327
Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity
Kaberg M; Edgren E; Hammarberg A; Weiland O
Article: JOURNAL OF VIRAL HEPATITIS. 2019;26(3):337-349
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
Flamm S; Mutimer D; Asatryan A; Wang S; Rockstroh J; Horsmans Y; Kwo PY; Weiland O; Villa E; Heo J; Gane E; Ryder SD; Welzel TM; Ruane PJ; Agarwal K; Ng TI; Xue Z; Lovell SS; Krishnan P; Kopecky-Bromberg S; Trinh R; Mensa FJ; Wyles DL
Article: INFECTIOUS DISEASES. 2019;51(2):131-139
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
Isakov V; Chulanov V; Abdurakhmanov D; Burnevich E; Nurmukhametova E; Kozhevnikova G; Gankina N; Zhuravel S; Romanova S; Hyland RH; Lu S; Svarovskaia ES; Mcnally J; Brainard DM; Ivashkin V; Morozov V; Bakulin I; Lagging M; Zhdanov K; Weiland O
Article: JOURNAL OF VIRAL HEPATITIS. 2018;25(12):1452-1461
Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination
Kaberg M; Naver G; Hammarberg A; Weiland O
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(7):971-978
Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
Frisk P; Aggefors K; Cars T; Feltelius N; Loov SA; Wettermark B; Weiland O
Article: JOURNAL OF VIRAL HEPATITIS. 2018;25(7):802-810
Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C
Hedenstierna M; Nangarhari A; El-Sabini A; Weiland O; Aleman S
Article: INFECTIOUS DISEASES. 2017;49(10):728-736
Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program
Kaberg M; Hammarberg A; Lidman C; Weiland O
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(9):1022-1028
Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis
Borssen AD; Marschall H-U; Bergquist A; Rorsman F; Weiland O; Kechagias S; Nyhlin N; Verbaan H; Nilsson E; Werner M
Article: MEDICINE. 2017;96(34):e7708
Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis A cohort study
Borssen AD; Palmqvist R; Kechagias S; Marschall H-U; Bergquist A; Rorsman F; Weiland O; Verbaan H; Nyhlin N; Nilsson E; Werner M
Article: PLOS ONE. 2017;12(7):e0179764
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Farkkila M; Balslev U; Belard E; Ovrehus A; Kjaer MS; Krarup H; Roge BT; Hallager S; Madsen LG; Laursen AL; Lagging M; Weis N
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(5):585-588
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Article: JOURNAL OF HEPATOLOGY. 2017;66(3):485-493
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernandez-Rodriguez CM; Aleman S; Ganne-Carrie N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
Article: BMC INFECTIOUS DISEASES. 2017;17(1):45
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
Young J; Weis N; Hofer H; Irving W; Weiland O; Giostra E; Manuel Pascasio J; Castells L; Prieto M; Postema R; Lefevre C; Evans D; Bucher HC; Luis Calleja J
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(1):61-68
Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden
Busch K; Waldenstrom J; Lagging M; Aleman S; Weiland O; Kovamees J; Duberg A-S; Soderholm J
Article: MEDICINE. 2016;95(49):e5617
Low mortality but increasing incidence of Staphylococcus aureus endocarditis in people who inject drugs Experience from a Swedish referral hospital
Asgeirsson H; Thalme A; Weiland O
Article: GUT. 2016;65(11):1861-1870
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Article: CLINICAL INFECTIOUS DISEASES. 2016;63(6):723-729
Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Article: LIVER TRANSPLANTATION. 2016;22(4):446-458
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
Fontana RJ; Brown RSJ; Moreno-Zamora A; Prieto M; Joshi S; Londono M-C; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri S-M; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Article: THERAPEUTIC DRUG MONITORING. 2015;37(6):745-750
High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients
Lindahl K; Hornfeld E; Stahle L; Carlsson T; Weiland O; Parke A; Schvarcz R
Article: CLINICAL MICROBIOLOGY AND INFECTION. 2015;21(8):772-778
Incidence and outcome of Staphylococcus aureus endocarditis-a 10-year single-centre northern European experience
Asgeirsson H; Thalme A; Kristjansson M; Weiland O
Article: GUT. 2015;64(6):948-956
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
Hezode C; Hirschfield GM; Ghesquiere W; Sievert W; Rodriguez-Torres M; Shafran SD; Thuluvath PJ; Tatum HA; Waked I; Esmat G; Lawitz EJ; Rustgi VK; Pol S; Weis N; Pockros PJ; Bourliere M; Serfaty L; Vierling JM; Fried MW; Weiland O; Brunetto MR; Everson GT; Zeuzem S; Kwo PY; Sulkowski M; Braeu N; Hernandez D; McPhee F; Wind-Rotolo M; Liu Z; Noviello S; Hughes EA; Yin PD; Schnittman S
Article: INFECTIOUS DISEASES. 2015;47(4):209-217
Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation
Ackefors M; Castedal M; Dahlgard O; Verbaan H; Gjertsen H; Wernerson A; Weiland O
Article: PLOS ONE. 2015;10(3):e0118643
Low Levels of Microbial Translocation Marker LBP Are Associated with Sustained Viral Response after Anti-HCV Treatment in HIV-1/HCV Co-Infected Patients
Nystrom J; Stenkvist J; Haggblom A; Weiland O; Nowak P
Article: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2015;41(6):532-543
Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure
Hedenstierna M; Weiland O; Brass A; Bankwitz D; Behrendt P; Uhnoo I; Aleman S; Cardell K; Fryden A; Norkrans G; Eilard A; Glaumann H; Pietschmann T; Sallberg M; Brenndorfer ED
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2015;50(2):217-223
Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis - a long-term follow-up study in 634 Swedish patients
Borssen AD; Almer S; Prytz H; Wallerstedt S; Friis-Liby I-L; Bergquist A; Nyhlin N; Hultcrantz R; Sangfelt P; Weiland O; Lindgren S; Verbaan H; Werner M
Article: PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2015;34(2):140-144
Low Mortality of Staphylococcus aureus Bacteremia in Icelandic Children Nationwide Study on Incidence and Outcome
Asgeirsson H; Gudlaugsson O; Kristinsson KG; Vilbergsson GR; Heiddal S; Haraldsson A; Weiland O; Kristjansson M
Article: LANCET INFECTIOUS DISEASES. 2015;15(1):27-35
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Article: LAKARTIDNINGEN. 2014;111(51-52):2280-2281
[Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent].
Weiland O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2014;46(9):624-632
High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort
Stenkvist J; Weiland O; Sonnerborg A; Blaxhult A; Falconer K
Article: PLOS ONE. 2014;9(8):e105665
The Dynamic Relationship between Innate Immune Biomarkers and Interferon-Based Treatment Effects and Outcome in Hepatitis C Virus Infection Is Altered by Telaprevir
Malone DFG; Falconer K; Weiland O; Sandberg JK
Article: GASTROENTEROLOGY. 2014;147(2):359-365.e1
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Muellhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues LJ; Hu YB; Podsadecki T; Bernstein B
Article: JOURNAL OF HEPATOLOGY. 2014;61(2):228-234
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study
Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;370(21):1993-2001
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian M; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hezode C; Esteban R
Article: JOURNAL OF HEPATOLOGY. 2014;60(5):913-919
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection
Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;370(17):1594-1603
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
Article: PLOS ONE. 2013;8(11):e80172
Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection
Ydreborg M; Westin J; Rembeck K; Lindh M; Norrgren H; Holmberg A; Wejstal R; Norkrans G; Cardell K; Weiland O; Lagging M
Article: JOURNAL OF VIRAL HEPATITIS. 2013;20(11):770-778
Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
Ackefors M; Nystrom J; Wernerson A; Gjertsen H; Sonnerborg A; Weiland O
Article: MOLECULAR THERAPY. 2013;21(9):1796-1805
Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
Weiland O; Ahlen G; Diepolder H; Jung M-C; Levander S; Fons M; Mathiesen I; Sardesai NY; Vahlne A; Frelin L; Sallberg M
Article: CLINICAL INFECTIOUS DISEASES. 2013;57(2):230-236
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stal P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
Article: JOURNAL OF VIRAL HEPATITIS. 2013;20(4):e82-e89
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin
Lindh M; Arnholm B; Bjorkman P; Hellstrand K; Lagging M; Nilsson S; Wahlberg T; Wallmark E; Weiland O; Wejstal R; Westin J; Widell A; Norkrans G
Article: JOURNAL OF VIRAL HEPATITIS. 2013;20(3):193-199
HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism
Stenkvist J; Sonnerborg A; Weiland O
Article: JOURNAL OF VIRAL HEPATITIS. 2012;19(9):635-639
Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation
Ackefors M; Gjertsen H; Wernerson A; Weiland O
Article: GASTROENTEROLOGY. 2011;141(3):881-889.e1
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
Foster GR; Hezode C; Bronowicki J-P; Carosi G; Weiland O; Verlinden L; van Heeswijk R; van Baelen B; Picchio G; Beumont M
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2011;364(25):2417-2428
Telaprevir for Retreatment of HCV Infection
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Muellhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2011;46(6):760-766
Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs
Andersen ES; Weiland O; Leutscher P; Krarup H; Westin J; Moessner B; Konopski Z; Frigstad S-O; Kjaer M; Christensen PB; Weis N
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2010;42(6-7):533-539
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients
Nilsson J; Weiland O
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2010;45(4):457-467
Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response
Werner M; Wallerstedt S; Lindgren S; Almer S; Bjornsson E; Bergquist A; Prytz H; Sandberg-Gertzen H; Hultcrantz R; Sangfelt P; Weiland O; Ohlsson B; Danielsson A
Article: LAKARTIDNINGEN. 2009;106(50-51):3420-3423
[Measurement of liver elasticity can differentiate high and low grade fibrosis. New method can reduce the need of liver biopsy in chronic hepatitis C].
Wejdmark A; Weiland O
Article: LAKARTIDNINGEN. 2009;106(50-51):3412-3418
[Elastography--a new tool for diagnosis of chronic liver diseases. Might replace liver biopsy, but not always].
Stål P; von Seth E; Bergquist A; Nemeth A; Weiland O
Article: JOURNAL OF IMMUNOLOGY. 2009;183(10):6612-6618
Expansion of Functionally Skewed CD56-Negative NK Cells in Chronic Hepatitis C Virus Infection: Correlation with Outcome of Pegylated IFN-α and Ribavirin Treatment
Gonzalez VD; Falconer K; Bjorkstrom NK; Blom KG; Weiland O; Ljunggren H-G; Alaeus A; Sandberg JK
Article: LAKARTIDNINGEN. 2009;106(14):1016-1019
[Fibrosis indexes reduce the need of liver biopsy in chronic hepatitis C].
Björklund J; Aleman S; Weiland O
Article: JOURNAL OF HEPATOLOGY. 2009;50(2):388-393
Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients
Werner M; Almer S; Prytz H; Lindgren S; Wallerstedt S; Bjoersson E; Bergquist A; Sandberg-Gertzen H; Hultcrantz R; Sangfelt P; Weiland O; Danielsson A
Article: JOURNAL OF IMMUNOLOGY. 2008;181(6):4219-4228
Elevated numbers of FcγRIIIA⁺ (CD16⁺) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection
Bjorkstrom NK; Gonzalez VD; Malmberg K-J; Falconer K; Alaeus A; Nowak G; Jorns C; Ericzon B-G; Weiland O; Sandberg JK; Ljunggren H-G
Article: JOURNAL OF VIRAL HEPATITIS. 2008;15(9):641-645
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin
Weiland O; Hollander A; Mattsson L; Glaumann H; Lindahl K; Schvarcz R; Lindh G; Enquist R; Quist A
Article: LAKARTIDNINGEN. 2008;105(19):1371-1372
[Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study].
Weiland O
Article: JOURNAL OF MEDICAL VIROLOGY. 2008;80(5):803-807
Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: Comparison between two HCV RNA quantitation methods
Carlsson T; Quist A; Weiland O
Article: AIDS. 2008;22(7):899-901
Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy
Olle K; Anders S; Ola W
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2008;43(10):1232-1240
Epidemiology and the initial presentation of autoimmune hepatitis in Sweden:: A nationwide study
Werner M; Prytz H; Ohlsson B; Almer S; Bjornsson E; Bergquist A; Wallerstedt S; Sandberg-Gertzen H; Hultcrantz R; Sangfelt P; Weiland O; Danielsson A
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2008;43(11):1378-1386
Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis
Syed E; Rahbin N; Weiland O; Carlsson T; Oksanen A; Birk M; Davidsdottir L; Hagen K; Hultcrantz R; Aleman S
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2008;40(3):259-265
High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation
Hornfeldt E; Gjertsen H; Weiland O
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2008;43(4):465-472
A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: A retrospective follow-up survey in the clinical setting
Sangfelt P; Uhnoo I; Reichard O; Weiland O
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2007;42(7):867-877
Productivity improvements in hepatitis C treatment:: Impact on efficacy, cost, cost-effectiveness and quality of life
Lidgren M; Hollander A; Weiland O; Jonsson B
Article: JOURNAL OF MEDICAL VIROLOGY. 2007;79(6):701-713
Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C
Desombere I; Van Vlierberghe H; Weiland O; Hultgren C; Sallberg M; Quiroga J; Carreno V; Leroux-Roels G
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2007;42(2):247-255
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Article: LAKARTIDNINGEN. 2006;103(26-27):2045-2048
[Long-term treatment with interferon-alpha can induce sarcoidosis. The connection can be stronger than earlier believed].
Grunewald J; Andersson O; Berlin M; Bradley M; Zetterberg G; Weiland O; Eklund A
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2006;41(5):577-585
Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C
Hollander A; Foster GR; Weiland O
Article: GUT. 2006;55(2):266-274
Relation between viral fitness and immune escape within the hepatitis C virus protease
Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2006;38(1):55-58
Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls
Olsen BR; Axelsson-Olsson D; Thelin A; Weiland O
Article: JOURNAL OF VIRAL HEPATITIS. 2005;12(5):473-480
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
Article: JOURNAL OF HEPATOLOGY. 2005;42(5):615-624
Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients
Alberti A; Clumeck N; Collins S; Gerlich W; Lundgren J; Palù G; Reiss P; Thiebaut R; Weiland O; Yazdanpanah Y; Zeuzem S
Article: GUT. 2004;53(10):1504-1508
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy
Veldt BJ; Saracco G; Boyer N; Cammà C; Bellobuono A; Hopf U; Castillo I; Weiland O; Nevens F; Hansen BE; Schalm SW
Article: JOURNAL OF HEPATOLOGY. 2004;40(6):971-978
Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses
Hultgren C; Desombere I; Leroux-Roels G; Quiroga JA; Carren V; Nilsson B; Weiland O; Sällberg M
Article: GENE THERAPY. 2004;11(6):522-533
Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene
Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2004;39(2):164-167
Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre
Hollander A; Glaumann H; Weiland O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2004;36(3):182-185
Serum ALT levels as a surrogate marker for serum HBV DNA levels in HBeAg-negative pregnant women
Sangfelt P; Von Sydow M; Uhnoo I; Weiland O; Lindh G; Fischler B; Lindgren S; Reichard O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2003;35(8):445-451
Chronic hepatitis C:: Updated Swedish consensus
Wejstål R; Alaeus A; Fischler B; Reichard O; Uhnoo I; Weiland O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2003;35(6-7):401-403
Infectious aetiology of jaundice among pregnant women in Angola
Strand RT; Franque-ranque M; Bergström S; Weiland O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2003;35(3):180-185
Hepatitis C virus RNA levels during initial induction or standard interferon therapy: Influence of continued treatment on sustained response
Balciuniene L; Carlsson T; Ambrozaitis A; Reichard O; Weiland O
Article: HEPATOLOGY. 2002;36(4):973-977
Predictive value of ALT levels for histologic findings in chronic hepatitis C:: A European collaborative study
Pradat P; Alberti A; Poynard T; Esteban JI; Weiland O; Marcellin P; Badalamenti S; Trépo C
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2002;37(10):1228-1234
Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin
Carlsson T; Weiland O; Reichard O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2002;34(7):505-511
Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: A pilot study
Sangfelt P; Uhnoo I; Hollander A; Lindh G; Weiland O
Article: JOURNAL OF HEPATOLOGY. 2002;36(3):408-416
Features of the CD4⁺ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels
Rico MA; Quiroga JA; Subirá D; Garcia E; Castañón S; Sällberg M; Leroux-Roels G; Weiland O; Pardo M; Carreño V
Journal article: LAKARTIDNINGEN. 2001;98(36):3780-3784
[Give all children vaccine against hepatitis B!].
Weiland O
Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 6):1299-1308
Humoral and CD4⁺ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein:: NS3 primes Th 1-like responses more effectively as a DNA-based immunogen than as a recombinant protein
Lazdina U; Hultgren C; Frelin L; Chen M; Lodin K; Weiland O; Leroux-Roels G; Quiroga JA; Peterson DL; Milich DR; Sällberg M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2001;33(11):838-842
Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy
Carlsson T; Reichard O; Weiland O
Article: JOURNAL OF MEDICAL VIROLOGY. 2000;62(3):334-344
Humoral and cellular immune responses to the GB virus C hepatitis G virus envelope 2 protein
Lazdina U; Hultgren C; Chen M; Fischler B; Weiland O; Mushahwar IK; Sällberg M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2000;32(5):465-470
Chronic hepatitis C -: Swedish experts' meeting recommends combination treatment
Wejstål R; Fischler B; Glaumann H; Norkrans G; Reichard O; Sönnerborg A; Uhnoo I; Weiland O
Article: CLINICAL INFECTIOUS DISEASES. 1999;29(6):1575-1577
Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection
Hultgren C; Weiland O; Milich DR; Sällberg M
Article: LAKARTIDNINGEN. 1999;96(44):4795-4800
[Recommendations from a Swedish meeting of experts. Hepatitis C is to be treated with the combination of interferon and ribavirin].
Wejstål R; Fischler B; Glaumann H; Norkrans G; Reichard O; Sönnerborg A; Uhnoo I; Weiland O
Article: GASTROENTEROLOGY. 1999;117(2):408-413
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
Schalm SW; Weiland O; Hansen BE; Milella M; Lai FY; Hollander A; Michielsen PP; Bellobuono A; Chemello L; Pastore G; Chen DS; Brouwer JT
Article: JOURNAL OF VIRAL HEPATITIS. 1999;6(3):237-242
Histological and virological long-term outcome in patients treated with interferon-α2b and ribavirin for chronic hepatitis C
Schvarcz R; Glaumann H; Reichard O; Weiland O
Article: JOURNAL OF HEPATOLOGY. 1999;30(5):783-787
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
Reichard O; Glaumann H; Frydén A; Norkrans G; Wejstål R; Weiland O
Article: LAKARTIDNINGEN. 1999;96(4):294-296
[The risk of disease transmission via blood and blood products is always there. It is important for prevention to be a step ahead].
Weiland O
Article: GASTROENTEROLOGY. 1999;116(1):135-143
Limited humoral immunity in hepatitis C virus infection
Chen M; Sällberg M; Sönnerborg A; Weiland O; Mattsson L; Jin L; Birkett A; Peterson D; Milich DR
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1999;31(2):115-118
Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C
Weiland O; Braconier JH; Frydén A; Norkrans G; Reichard O; Uhnoo I
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1999;31(1):93-95
The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination
Carlsson T; Struve J; Sönnerborg A; Weiland O
Article: JOURNAL OF GENERAL VIROLOGY. 1998;79:2381-2391
The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses
Hultgren C; Milich DR; Weiland O; Sällberg M
Article: JOURNAL OF MEDICAL VIROLOGY. 1998;56(1):33-38
Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment
Odeberg J; Yun ZB; Sönnerborg A; Weiland O; Lundeberg J
Article: HEPATOLOGY. 1998;28(1):219-224
Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein
Chen M; Sällberg M; Sönnerborg A; Jin L; Birkett A; Peterson D; Weiland O; Milich DR
Article: JOURNAL OF MEDICAL VIROLOGY. 1998;54(2):75-79
GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors
Shev S; Björkman P; Norkrans G; Foberg U; Frydén A; Lindh G; Lindholm A; Weiland O; Widell A
Article: LANCET. 1998;351(9096):83-87
Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1998;30(5):441-446
Comparison of 3 quantitative HCV RNA assays -: Accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Article: JOURNAL OF INFECTIOUS DISEASES. 1997;175(6):1294-1301
Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy
Zhang ZX; Milich DR; Peterson DL; Birkett A; Schvarcz R; Weiland O; Sallberg M
Article: RESEARCH IN VIROLOGY. 1997;148(3):233-237
Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions
Yun Z; Johansson B; Weiland O; Sonnerborg A
Article: JOURNAL OF HEPATOLOGY. 1997;26(5):961-966
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C - Meta-analysis of individual patient data from European centers
Schalm SW; Hansen BE; Chemello L; Bellobuono A; Brouwer JT; Weiland O; Cavalletto L; Schvarcz R; Ideo G; Alberti A
Article: LAKARTIDNINGEN. 1997;94(14):1302-1304
[Blood exposure during labor. A common risk of contamination that may be reduced].
Eriksson M; Jarmar K; Weiland O; Westgren M
Article: JOURNAL OF HEPATOLOGY. 1996;25(5):591-598
Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
Dusheiko G; Main J; Thomas H; Reichard O; Lee C; Dhillon A; Rassam S; Fryden A; Reesink H; Bassendine M; Norkrans G; Cuypers T; Lelie N; Telfer P; Watson J; Weegink C; Sillikens P; Weiland O
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1996;31(6):604-611
Factors influencing the response to interferon therapy in chronic hepatitis C - Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells
Grander D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Bjorklund AC; Befrits R; Bjorkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 1996;12(3):319-322
Utility of an anonymous questionnaire for the identification of a primary transmission route and possible secondary transmission in adults with acute hepatitis B virus infection
Struve J; Giesecke J; Lindh G; Weiland O
Article: JOURNAL OF INFECTIOUS DISEASES. 1996;173(4):992-996
Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load
Yun ZB; Odeberg J; Lundeberg J; Weiland O; Uhlen M; Sonnerborg A
Article: LAKARTIDNINGEN. 1996;93(10):884-888
[Hepatitis B is an occupational risk for health personnel. Preventive vaccination is recommended].
Struve J; Aronsson B; Forsgren M; Frenning B; von Sydow M; Weiland O
Article: HEMATOLOGY. 1996;1(1):75-78
Activated Cellular Immunity in Chronic Hepatitis C.
Diez-Ruiz A; Norkrans G; Wejstal R; Weiland O; Tilz GP; Wachter H; Fuchs D
Article: JOURNAL OF INFECTION. 1995;31(3):205-209
RISK-FACTORS FOR HEPATITIS-A, HEPATITIS-B AND HEPATITIS-C VIRUS-INFECTION AMONG SWEDISH EXPATRIATES
STRUVE J; NORRBOHM O; STENBECK J; GIESECKE J; WEILAND O
Article: INFECTION. 1995;23(5):253-257
HCV GENOTYPES IN SWEDISH BLOOD-DONORS AS CORRELATED TO EPIDEMIOLOGY, LIVER-DISEASE AND HEPATITIS-C VIRUS-ANTIBODY PROFILE
SHEV S; WIDELL A; FOBERG U; FRYDEN A; HERMODSSON S; LINDH G; LINDHOLM A; MANSSON S; WEILAND O; NORKRANS G
Article: LAKARTIDNINGEN. 1995;92(18):1920-1922
[Half of the patients respond to interferon treatment. Combination therapy is an alternative in chronic hepatitis C].
Weiland O; Norkrans G; Frydén A; Braconier JH
Article: JOURNAL OF MEDICAL VIROLOGY. 1995;46(1):43-47
COMBINED TREATMENT WITH INTERFERON-ALPHA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS-C IN PATIENTS WITH A PREVIOUS NONRESPONSE OR NONSUSTAINED RESPONSE TO INTERFERON ALONE
SCHVARCZ R; YUN ZB; SONNERBORG A; WEILAND O
Article: HEPATOLOGY. 1995;21(4):918-922
2-YEAR BIOCHEMICAL, VIROLOGICAL, AND HISTOLOGICAL FOLLOW-UP IN PATIENTS WITH CHRONIC HEPATITIS-C RESPONDING IN A SUSTAINED FASHION TO INTERFERON ALFA-2B TREATMENT
REICHARD O; GLAUMANN H; FRYDEN A; NORKRANS G; SCHVARCZ R; SONNERBORG A; YUN ZB; WEILAND O
Article: JOURNAL OF HEPATOLOGY. 1995;23:17-21
Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
Schvarcz R; Ando Y; Sonnerborg A; Weiland O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1995;27(6):543-546
Hepatitis E virus infections in patients with acute hepatitis non-A-D in Sweden
Johansson PJH; Mushahwar IK; Norkrans G; Weiland O; Nordenfelt E
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1995;27(4):319-324
EFFICACY OF HUMAN-LEUKOCYTE ALPHA-INTERFERON TREATMENT FOR CHRONIC HEPATITIS-C VIRUS-INFECTION
WEILAND O; CHEN M; LINDH G; MATTSSON L; SCHVARCZ R; SONNERBORG A; WAHL M; WEJSTAL R
Article: INFECTION. 1995;23(1):42-45
RESPONSE TO A BOOSTER DOSE 18 MONTHS AFTER A LOW ANTI-HBS RESPONSE (10-99 IU/I) TO 3 DOSES OF INTRADERMALLY OR INTRAMUSCULARLY ADMINISTERED RECOMBINANT HEPATITIS-B VACCINE
STRUVE J; ARONSSON B; FRENNING B; FORSGREN M; WEILAND O
Show more

All other publications

Letter: HEPATOLOGY. 2021;74(2):1127-1128
Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs "Fair Treatment" by Us REPLY
Kamal H; Weiland O; Aleman S
Review: LIVER INTERNATIONAL. 2020;40:61-66
Hepatitis C elimination - Macro-elimination
Kaberg M; Weiland O
Review: INFECTIOUS DISEASES. 2020;52(1):1-22
Management of hepatitis B virus infection, updated Swedish guidelines
Westin J; Aleman S; Castedal M; Duberg A-S; Eilard A; Fischlere B; Kampmann C; Lindahl K; Lindh M; Norkrans G; Stenmark S; Weiland O; Wejstal R
Letter: JOURNAL OF HEPATOLOGY. 2019;70(5):1019-1023
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
Wyles D; Weiland O; Yao B; Weilert F; Dufour J-F; Gordon SC; Stoehr A; Brown A; Mauss S; Zhang Z; Pilot-Matias T; Rodrigues LJ; Mensa FJ; Poordad F
Review: INFECTIOUS DISEASES. 2018;50(8):569-583
Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017
Lagging M; Wejstal R; Duberg A-S; Aleman S; Weiland O; Westin J
Review: INFECTIOUS DISEASES. 2018;50(3):175-192
Staphylococcus aureus bacteraemia and endocarditis - epidemiology and outcome: a review
Asgeirsson H; Thalme A; Weiland O
Corrigendum: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(11):i-(i)
Correction to: Castedal et al., IFN-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Review: INFECTIOUS DISEASES. 2017;49(8):561-575
Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016
Lagging M; Wejstal R; Norkrans G; Karlstrom O; Aleman S; Weiland O; Castedal M; Westin J
Review: INFECTIOUS DISEASES. 2016;48(4):251-261
Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations
Lagging M; Wejstal R; Norkrans G; Karlstrom O; Aleman S; Weiland O; Castedal M; Josephson F
Editorial: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2014;46(12):817
Editorial - An introduction to the new INFECTIOUS DISEASES
Taernvik A; Weiland O
Review: JOURNAL OF HEPATOLOGY. 2014;61(4):957-961
Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals
Stenkvist J; Nystrom J; Faconer K; Sonnerborg A; Weiland O
Other: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2014;46(8):545-546
In memoriam-Professor Ragnar Norrby (1943-2014)
Taernvik A; Weiland O
Review: DRUG RESISTANCE UPDATES. 2013;16(3-5):60-67
Containing "The Great Houdini" of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C
Ahlen G; Frelin L; Brenndorfer ED; Brass A; Weiland O; Chen M; Sallberg M
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(7):502-521
Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations
Lagging M; Duberg A-S; Wejstal R; Weiland O; Lindh M; Aleman S; Josephson F
Meeting abstract: JOURNAL OF HEPATOLOGY. 2010;52:S27
ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209
Foster GR; Hezode C; Bronowicki J-P; Carosi G; Weiland O; Verlinden L; van Heeswijk R; Van Baelen B; Picchio G; Beaumont-Mauviel M
Review: EXPERT OPINION ON BIOLOGICAL THERAPY. 2009;9(7):805-815
DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target
Sallberg M; Frelin L; Weiland O
Editorial: JOURNAL OF HEPATOLOGY. 2009;51(1):4-7
What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: Viral dynamics, viral levels at certain time points, or a combination of both?
Weiland O
Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S22
ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209
Foster GR; Hezode C; Bronowicki J-P; Carosi G; Weiland O; Verlinden L; van Heeswijk R; Vangeneugden T; Picchio G; Beumont-Mauviel M
Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S18-S19
A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS C
Sallberg MM; Frelin L; Diepolder H; Jung M-C; Mathiesen I; Fons M; Hultcrantz R; Carlsson T; Weiland O
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2009;41(6-7):389-402
Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations
Lagging M; Wejstal R; Uhnoo I; Gerden B; Fischler B; Friman S; Josephson F; Karlstrom O; Sangfelt P; Schvarz R; Weiland O
Meeting abstract: JOURNAL OF HEPATOLOGY. 2008;48:S331-S332
Epidemiology and the initial presentation of autoimmune hepatitis type 1 in Sweden, a nationwide study
Werner M; Prytz H; Ohlsson B; Almer S; Bjornsson E; Bergquist A; Wallerstedt S; Sandberg-Gertzen H; Hultcrantz R; Sangfelt P; Weiland O; Danielsson A
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2008;40(6-7):436-450
Treatment of chronic hepatitis B infection:: An update of Swedish recommendations
Lindh M; Uhnoo I; Blackberg J; Duberg A-S; Friman S; Fischler B; Karlstrom O; Norkrans G; Reichard O; Sangfeldt P; Soderstrom A; Sonnerborg A; Weiland O; Wejstal R; Wistrom J
Review: LANCET INFECTIOUS DISEASES. 2007;7(6):410-419
Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?
Zuckerman J; van Hattum J; Cafferkey M; Gjorup I; Hoel T; Rummukainen M-L; Weiland O
Published conference paper: TRANSPLANTATION PROCEEDINGS. 2006;38(8):2675-2676
Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm
Gjertsen H; Weiland O; Oksanen A; Soderdahl G; Broome U; Ericzon B-G
Meeting abstract: JOURNAL OF CLINICAL VIROLOGY. 2006;36:S142
Retreatment with peginterferon alpha-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients in whom pegylated interferon alpha-2b (12KD)/ribavirin has failed:: planned week-12 efficacy and safety analysis of the repeat study
Marcellin P; Teuber G; Freilich B; Weiland O; Di Bisceglie A; Brandao-Mello C; Canva V; Andreone P; Rai R; Jensen D
Meeting abstract: JOURNAL OF HEPATOLOGY. 2006;44:S230
135μg Peg-IFN alpha-2a in combination with weight-based ribavirin for genotype 2 and 3 is highly efficacious
Weiland O; Schvarcz R; Mattsson L; Glaumann H; Hollander A; Enquist R; Quist A
Meeting abstract: JOURNAL OF HEPATOLOGY. 2006;44:S7
Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12KD)/ribavirin non-responders:: Interim analysis of the repeat study
Marcellin P; Teuber G; Canva V; Weiland O; Di Bisceglie A; Brandao-Mello C; Freilich B; Jensen D
Published conference paper: JOURNAL OF HEPATOLOGY. 2006;44(1):97-103
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
Corrigendum: JOURNAL OF HEPATOLOGY. 2005;43(6):1098
Short statement of the first european consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients (vol 42, pg 615, 2005)
Alberti A; Clumeck N; Collins S; Gerlich W; Lundgren J; Palù G; Reiss P; Thiebaut R; Weiland O; Yazdanpanah Y; Zeuzem S
Meeting abstract: JOURNAL OF HEPATOLOGY. 2004;40:154
Combination therapy with peginterferon alfa-2a (40kd) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection:: Individual estimated probability of sustained virological response (SVR)
Weiland O; Fried MW; Hadziyannis SJ; Foster GR; Messinger D; Freivogel K; Chaneac M
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2001;33(8):572-580
GB virus C/hepatitis G virus
Halasz R; Weiland O; Sällberg M
Published conference paper: JOURNAL OF INFECTIOUS DISEASES. 2000;182(6):1756-1760
The GB virus C/hepatitis G virus replicates in hepatocytes without causing liver disease in healthy blood donors
Halasz R; Sällberg M; Lundholm S; Andersson G; Lager B; Glaumann H; Weiland O
Editorial: JOURNAL OF HEPATOLOGY. 2000;33(3):482-484
New pieces to the hepatitis C treatment puzzle
Weiland O
Corrigendum: JOURNAL OF MEDICAL VIROLOGY. 2000;61(3):409
GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors. (vol 54, pg 74, 1998)
Shev S; Bjorkman P; Norkrans G; Foberg U; Fryden A; Lindh G; Lindholm A; Weiland O; Widell A
Review: FORUM - TRENDS IN EXPERIMENTAL AND CLINICAL MEDICINE. 2000;10(1):22-28
Interferon and ribavirin combination therapy: indications and schedules.
Weiland O
Other: JOURNAL OF HEPATOLOGY. 1999;31:3-8
EASL International Consensus Conference on Hepatitis C -: Paris, 26-27 February 1999 -: Consensus statement (Reprinted from Journal of Hematology, vol 30, pg 956-961, 1999)
Marcellin P; Alberti A; Dusheiko G; Esteban R; Manns M; Shouval D; Weiland O; Williams R; Benhamou JP; Rodes J; Alter H; Bismuth H; Desmet V; Guardia J; Heathcote J; Lok A; Maddrey WC; Zum Büschenfelde KHM; Pagliaro L; Paumgartner G; Sherlock S; Abrignani S; Alberti A; Alter M; Bonino F; Bortolotti F; Bréchot C; de Moura MC; Carreño V; Colombo M; Craxi A; Davis G; De Francesco R; Degos F; Di Bisceglie A; Dienes H; Dusheiko G; Esteban J; Esteban R; Farci P; Ferrari C; Foster G; Hadziyannis S; Hoofnagle J; Koff R; Lavanchy D; Lindsay K; Lunel F; Manns M; Marcellin P; Mondelli M; Nalpas B; Naoumov N; Pawlotsky JM; Pol S; Pontisso P; Poynard T; Prieto J; Rizzetto M; Roggendorf M; Moreno MR; Samuel D; Sanchez-Tapias J; Schalm S; Shouval D; Simmonds P; Soriano V; Tassopoulos N; Thomas H; Trépo C; Van der Poel CL; Vogel W; Weiland O; Wejstal R; Williams R; Wright T; Zanetti A; Zarski JP; Zeuzem S; Zoulim F
Published conference paper: JOURNAL OF HEPATOLOGY. 1999;31:168-173
Treatment of naive patients with chronic hepatitis C
Weiland O
Corrigendum: LANCET. 1998;352(9134):1154
Can HCV infection be cleared? (vol 352, pg 669, 1998)
Weiland O
Editorial: LANCET. 1998;352(9129):669-670
Can HCV infection be cleared?
Weiland O
Review: LAKARTIDNINGEN. 1998;95(1-2):40-43
[Treatment response in chronic hepatitis C. Content of virus in serum is decisive for the outcome].
Weiland O; Danielsson A; Lööf L
Other: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1998;30(1):3
Stellan Bengtsson in memoriam
Braconier JH; Nilsson-Ehle I; Norrby R; Weiland O
Published conference paper: HEPATOLOGY. 1997;26(3):108S-111S
Therapy of hepatitis C: Alpha interferon and ribavirin
Reichard O; Schvarcz R; Weiland O
Published conference paper: DIGESTIVE DISEASES AND SCIENCES. 1996;41(12):131S-134S
Interferon-ribavirin combination therapy for chronic hepatitis C
Schalm SW; Brouwer JT; Chemello L; Alberti A; Bellobuono A; Ideo G; Schwartz R; Weiland O
Other: JOURNAL OF INFECTIOUS DISEASES. 1995;171(5):1356-1359
DISTINGUISHING ACUTE FROM SYMPTOMATIC CHRONIC HEPATITIS-C VIRUS (HCV) INFECTION BY SITE-DIRECTED SEROLOGY OF THE HCV STRUCTURAL PROTEINS
ZHANG ZX; CHEN M; SONNERBORG A; WEILAND O; SALLBERG M
Addendum: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1995;27(5):319-324
Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
Other: JOURNAL OF HEPATOLOGY. 1989;23:37-40
Panel discussion
Sherlock S; Main J; Trepo C; Weiland O; Brillanti S; Alberti A
Show more

Employments

Professor Emeritus/Emerita, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2027
Professor, Department of Medicine, Huddinge, Karolinska Institutet, 2021-2021
Professor, Senior, Department of Medicine, Huddinge, Karolinska Institutet, 2013-2020
Professor/Senior Physician, Department of Medicine, Huddinge, Karolinska Institutet, 1999-2013
Professor, Assistant/Senior Doctor, Department of Medicine, Huddinge, Karolinska Institutet, 1998-1998

Articles

All other publications

Employments

News from KI

Events from KI